

# *Inhibition of the voltage-gated potassium channel Kv1.5 by hydrogen sulfide attenuates remodeling through S-nitrosylation-mediated signaling*

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Open Access

Al-Owais, M. M., Hettiarachchi, N. T., Dallas, M. L. ORCID: <https://orcid.org/0000-0002-5190-0522>, Scragg, J. L., Lippiat, J. D., Holden, A. V., Steele, D. S. and Peers, C. (2023) Inhibition of the voltage-gated potassium channel Kv1.5 by hydrogen sulfide attenuates remodeling through S-nitrosylation-mediated signaling. *Communications Biology*, 6. 651. ISSN 2399-3642 doi: 10.1038/s42003-023-05016-5 Available at <https://centaur.reading.ac.uk/112378/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1038/s42003-023-05016-5>

Publisher: Nature Research

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in

the [End User Agreement](#).



[www.reading.ac.uk/centaur](http://www.reading.ac.uk/centaur)

## **CentAUR**

Central Archive at the University of Reading

Reading's research outputs online

## Inhibition of the voltage-gated potassium channel Kv1.5 by hydrogen sulfide attenuates remodeling through S-nitrosylation-mediated signaling

Moza M. Al-Owais<sup>1</sup> , Nishani T. Hettiarachchi<sup>2</sup>, Mark L. Dallas<sup>3</sup> , Jason L. Scragg<sup>2</sup>, Jonathan D. Lippiat<sup>1</sup> , Arun V. Holden<sup>1</sup> , Derek S. Steele<sup>1</sup> & Chris Peers<sup>2</sup>

The voltage-gated K<sup>+</sup> channel plays a key role in atrial excitability, conducting the ultra-rapid rectifier K<sup>+</sup> current ( $I_{Kur}$ ) and contributing to the repolarization of the atrial action potential. In this study, we examine its regulation by hydrogen sulfide (H<sub>2</sub>S) in HL-1 cardiomyocytes and in HEK293 cells expressing human Kv1.5. Pacing induced remodeling resulted in shortening action potential duration, enhanced both Kv1.5 channel and H<sub>2</sub>S producing enzymes protein expression in HL-1 cardiomyocytes. H<sub>2</sub>S supplementation reduced these remodeling changes and restored action potential duration through inhibition of Kv1.5 channel. H<sub>2</sub>S also inhibited recombinant hKv1.5, lead to nitric oxide (NO) mediated S-nitrosylation and activated endothelial nitric oxide synthase (eNOS) by increased phosphorylation of Ser1177, prevention of NO formation precluded these effects. Regulation of  $I_{Kur}$  by H<sub>2</sub>S has important cardiovascular implications and represents a novel and potential therapeutic target.

<sup>1</sup>School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK. <sup>2</sup>Division of Cardiovascular and Diabetes Research, LICAMM, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, UK. <sup>3</sup>Reading School of Pharmacy, University of Reading, Reading RG6 6UB, UK. ✉email: [M.Al-Owais@leeds.ac.uk](mailto:M.Al-Owais@leeds.ac.uk)

The cardiac action potential duration (APD) depends on cycle length, it decreases as heart rate increases as shown in dynamic and static APD restitution curves, which can be quantitatively explained by slow changes in intracellular compartmental ionic concentrations, sarcolemmal pump and exchanger activity, and the activation and inactivation properties of ionic channels<sup>1</sup>. However, APD can also be influenced by long term patterns of cardiac activity<sup>2</sup>, leading to changes in ion channel expression and associated currents<sup>3–5</sup>. Such changes have been demonstrated in vivo, following sustained periods of high frequency activity induced by repetitive stimulation<sup>6</sup>, or following sustained tachycardia<sup>7</sup> or atrial fibrillation<sup>8</sup> (AF). Comparable effects have been demonstrated in vitro, for example, in cultured mouse HL-1 atrial myocytes<sup>9</sup> or rat atrial cells<sup>10</sup>. This epigenetic “remodeling” takes hours or days to develop, and may involve changes in the expression, synthesis, transport, insertion or recycling of channels, their protein subunits and associated regulatory proteins<sup>3–5,11</sup>. However, remodelling can also occur due to downstream changes in the pathways that regulate ion channel function. Importantly, APD shortening can itself promote arrhythmias, e.g. in AF, APD shortening facilitates re-entry and sustains the arrhythmia<sup>12</sup>.

Electrophysiological changes in chronic AF involve down-regulation of L-type calcium current ( $I_{Ca,L}$ ), the transient outward current ( $I_{to}$ ) and upregulation of steady-state outward current, the inward rectifier potassium current ( $I_{K1}$ ) and the acetylcholine-activated potassium current ( $I_{KACH}$ )<sup>3,13</sup>. Computational modelling has shown that these changes in channel regulation (modelled by changes in maximal conductances) reproduce the shortened APDs characteristic of AF and emphasise the importance of changes in  $K^+$ -selective channels<sup>4,14,15</sup>. Although different pathophysiological mechanisms contribute to AF<sup>16–19</sup>, one key factor appears to be redox status. AF is clearly associated with increased reactive oxygen and nitrogen species (ROS/RNS), although their source within atrial tissue differs between the acute and chronic forms of AF<sup>20–24</sup>. Also associated with AF is the downregulation of endothelial nitric oxide synthase, (NOS3/eNOS) and reduced nitric oxide (NO) bioavailability<sup>25,26</sup>. There is an emerging view that specific targeting of ROS/RNS production, protection of target proteins, or control of NO bioavailability, may reduce or reverse the transcription and electrophysiological remodelling of AF<sup>20</sup>.

Numerous proteins have been implicated both as redox-sensitive and of central importance in AF<sup>24,27</sup>. In particular, the rapidly activating voltage-gated  $K^+$  channel Kv1.5, responsible for the ultrarapid delayed rectifier current  $I_{Kur}$  that contributes significantly to atrial repolarization<sup>28,29</sup> and is a potential therapeutic target. Expression of Kv1.5 is largely confined to the atria<sup>30</sup>, and it has been shown that reduction of  $I_{Kur}$  prolongs the duration of action potential in remodelled atrial cells<sup>31</sup>. Indeed, a high prevalence of deleterious AF-associated mutations has been identified in KCNA5, the gene encoding Kv1.5, causing both gain- and loss-of channel function in lone AF patients<sup>32,33</sup>. This seems paradoxical, but AF has been proposed to arise from (i) a prolonged effective refractory period, which increases the likelihood of early afterdepolarization arrhythmias, which could arise from loss-of-function Kv1.5 mutants<sup>34</sup> or (ii) a reduced effective refractory period, increasing the likelihood of re-entrant arrhythmias, which could arise from gain-of-function Kv1.5 mutants<sup>32</sup>. Thus, either excessive or insufficient Kv1.5 activity can lead to AF-associated arrhythmia.

The involvement of the biologically active gas hydrogen sulfide ( $H_2S$ ) in modulating cardiovascular functions<sup>35,36</sup> has been established over the past decade.  $H_2S$  is considered an important signaling molecule and along with NO and carbon monoxide (CO), are designated ‘gasotransmitters’<sup>36,37</sup>. Endogenous  $H_2S$  is a product of distinct, widely distributed enzymes; primarily derived from

L-cysteine via the enzymes cystathionine- $\gamma$ -lyase (CSE) and cystathionine- $\beta$ -synthase (CBS), but also from 3-mercaptopyruvate sulfurtransferase (3-MPST) along with cysteine aminotransferase (CAT)<sup>38</sup>. Within the cell cytosol or mitochondria,  $H_2S$  can be produced from the intracellular sulphur bound to proteins (sulfane sulfur) in a redox- or pH- dependent manner<sup>39</sup>.

While the modulation of Kv1.5 by NO and CO has been studied previously<sup>40,41</sup>, the effect of  $H_2S$  has not.  $H_2S$  is linked to diverse physiological functions including regulation of blood pressure<sup>42</sup>, and sulfhydryl modulation of smooth muscle  $K_{ATP}$  channels<sup>43,44</sup>. Therefore, in the present study, we identified and characterised the modulation of Kv1.5 by  $H_2S$ , in HL-1 cardiomyocytes in which electrical remodelling was induced by high frequency stimulation. We also investigated the underlying signaling pathways, which provide a novel and potentially important target for reversal of the electrical remodeling and the treatment of AF.


## Results

**Interval pacing of HL-1 cardiomyocytes causes electrical and cellular remodeling.** To study remodeling in vitro a high frequency (5 Hz) interval pacing protocol was applied to HL-1 cells in culture (for 8 h) before measurements of cellular or electrical electrophysiological parameters. Interval pacing resulted in electrical remodeling of spontaneous APs when compared to control non-paced cells. APD was measured at 50% (APD<sub>50</sub>) and 90% (APD<sub>90</sub>) of repolarization. The mean APD was reduced by approximately 30% at APD<sub>50</sub> and 35% at APD<sub>90</sub>; from  $139.2 \pm 8.3$  ms to  $96.9 \pm 7.2$  ms for APD<sub>50</sub> and from  $306.9 \pm 37.6$  ms to  $196.0 \pm 22.0$  ms for APD<sub>90</sub> ( $p$ -value = 0.001 and 0.0198 respectively; two-tailed unpaired  $t$  test  $n$  = 10). Figure 1a, shows representative spontaneous APs recorded in control non-paced HL-1 cell (upper) and in cell that had been subjected to 5 Hz interval pacing (lower). Figure 1b shows superimposed APs from the cells in Fig. 1a, to illustrate the intrinsic variability. In control unstimulated cells, the APD<sub>90</sub> had a coefficient of variation of 4.1% and its rhythmic activity had a cycle length of  $2.3 \pm 0.02$  s ( $N$  = 44), while the cell previously subjected to pacing had a coefficient of variation of 4.2% and a cycle length of  $3 \pm 0.07$  s ( $N$  = 36). In addition, irregular, short bursts of spontaneous activity were recorded in some cells after pacing (4 out of 10) as illustrated in the example shown in Fig. 1c with irregularity of intervals between spontaneous APs illustrated by a histogram (Fig. 1d) estimating the probability density for these intervals ( $N$  = 17,  $8.6 \pm 1.4$  s). Such bursts were not observed in control unstimulated cells.

The time course of the cellular changes was assessed using western blot analysis following pacing over an 8-hour period with measurements taken every 2 h. In paced cells, Kv1.5/ $I_{Kur}$  expression increased as a function of time Fig. 1e. The Mean  $\pm$  SEM of the normalized cumulative data is shown in Fig. 1f where the value at each time point is expressed relative to the measurement in unstimulated controls. Moreover,  $H_2S$ -generating enzymes CTH, CBS and 3MPST, were all detected in HL-1 cells (Fig. 1g) and the expression of these enzymes increased as a function of time during pacing (Fig. 1g, h and Supplementary Fig 2). The full blots of these can be found as a Supplementary Fig 1.

The use of diphenyl phosphine oxide-1 (DPO-1), a potent inhibitor of Kv1.5<sup>45</sup>, on paced HL-1 resulted in time dependant downregulation of Kv1.5 and to a lower degree the down regulation of  $H_2S$ -generating enzymes (Supplementary Fig 3).

**$H_2S$  inhibits recombinant Kv1.5.** To examine the modulation of Kv1.5 currents by  $H_2S$  in isolation, HEK293 cells expressing human Kv1.5 were continually perfused during a whole cell patch clamp recording as previously described<sup>41</sup>. The effect of  $H_2S$  on




**Fig. 1** Electrical and cellular remodeling in HL-1 cardiomyocytes via regular interval pacing AP recordings from control and paced HL-1 cardiomyocytes.

**a** Representative spontaneous AP recordings from a control unstimulated cell (upper) and a cell that had been subjected to high frequency interval pacing (lower). **b** Superimposed spontaneous APs (total 36) from a typical control (upper) or paced (lower) HL-1 myocyte, demonstrating that prior interval pacing results in shortening of spontaneous APs and a decrease in spontaneous AP frequency. **c** Example showing irregularity of intervals between spontaneous APs apparent in some cells after interval pacing. **d** The probability density histograms for these intervals ( $N = 17$ ,  $8.6 \pm 1.4$  sec). **e** Representative western blots for native  $I_{K_{ur}}$ /Kv1.5 after various interval pacing time periods (0–8 h) showing increased protein level when compared to control unstimulated conditions. **f** Summary mean ( $\pm$ s.e.m) band intensities as determined using ImageJ software ( $n = 6$ –7 experiments, one-way ANOVA with post hoc Bonferroni correction). **g** Representative western blots for  $H_2S$  producing enzymes at different pacing time periods (0–8 h) showing increased levels of CTH, CBS and MPST when compared to controls (time 0). **h** Summary mean ( $\pm$ s.e.m) percentage change of band intensities ( $n = 6$ –7 experiments).  $\beta$ -actin was used as loading control in all western blots. For all panels  $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$ .

hKv1.5 currents is shown in Fig. 2a, under control conditions before  $H_2S$  was added, the normalized peak amplitude of the current time series evoked by a step depolarization from  $-70$  to  $+50$  mV was steady, with a coefficient of variation of 1.59%. Switching the perfusate to one containing freshly prepared  $H_2S$ -forming compound NaHS, led to a slowly developing inhibition of hKv1.5 currents, which, was not reversed by a wash out.  $H_2S$  inhibited hKv1.5 currents by  $29.8 \pm 3.1\%$  ( $300 \mu M$ ;  $n = 10$ ).

Similar results were obtained when hKv1.5 expressing cells were exposed to a second  $H_2S$ -forming compound, GYY4137. A time series example is shown in Fig. 2b; before GYY4137 perfusion and up to 2 min, the measured normalized peak was steady, with a coefficient of variation of 1.66%. Following GYY4137 perfusion there was a slow gradual inhibition of the peak, by approximately a third; this inhibition was not reversed by 5 min wash out (Fig. 2b). The measured peak inhibition of hKv1.5 currents for all



**Fig. 2 H<sub>2</sub>S inhibits recombinant Kv1.5.** **a, b** Examples of time-series plots illustrating normalized peak current amplitudes evoked by step depolarizations from  $-70$  mV to  $+50$  mV in HEK293 cell expressing hKv1.5 before, during (horizontal bar) and after application of the fast-releasing H<sub>2</sub>S donor NaHS, or the slow-releasing H<sub>2</sub>S donor GYY4137 via perfusate. Insets show example currents under the conditions described; scale bars: 2 nA (vertical) and 50 ms (horizontal). **c, d** Mean ( $\pm$  s.e.m., values from 4–7 cells), concentration-response relationship illustrating the effects of H<sub>2</sub>S donor NaHS or GYY4137 on hKv1.5 expressed in HEK 293 cells. Inhibition was determined using currents evoked by step-depolarizations from  $-70$  mV to  $+50$  mV. Curves obtained by fitting data to Boltzmann function. **e** Mean ( $\pm$  s.e.m.;  $n = 9$ ;  $*P < 0.05$ ) current-density versus voltage relationships before (open circles) and during (solid circles) exposure to NaHS (300 μM). **f** Families of currents evoked in a HEK293 cell stably expressing hKv1.5 before (upper) and during exposure to NaHS (300 μM; lower). Currents evoked by step-depolarizations, applied up to  $+80$  mV in 10 mV increments from a holding potential of  $-70$  mV. Scale bars apply to both families of currents 2 nA (vertical) and 200 ms (horizontal).


examined cells was  $25.3 \pm 1.4\%$  (50 μM GYY4137;  $n = 6$ ). For these studies, GYY4137 was pre-dissolved and added to the reservoir for at least 30 min, as it is known to release H<sub>2</sub>S gas quite slowly. The inhibition of hKv1.5 by NaHS and GYY4137 was concentration-dependent, with EC values of  $383.6 \pm 30.5$  μM and  $91.3 \pm 3.01$  μM respectively measured at time point of 4 min (Fig. 2c, d). Control experiments for the examined duration, showing normalized hKv1.5 current amplitude can be found in Supplementary Fig 4a.

These observations indicate that H<sub>2</sub>S, derived from two distinct sources, irreversibly inhibits hKv1.5 currents. Currents were inhibited over a wide range of activating test potentials, exhibiting significant difference in their size with test potentials over  $+30$  mV (Fig. 2e) but without significant alteration of channel

kinetics in these examined test pulses (Fig. 2f and Supplementary Fig 4b).

**H<sub>2</sub>S inhibits native Kv1.5 in HL-1 cells and prolongs APD in atrial cardiomyocytes.** Figure 2 shows that H<sub>2</sub>S inhibits hKv1.5 currents in HEK293 cells expressing the recombinant channels. To further assess whether H<sub>2</sub>S may also inhibit native I<sub>Kur</sub> currents, (generated primarily via Kv1.5 in the atrial tissue), we examined its effect in HL-1 cells where the role I<sub>Kur</sub> plays in the AP is more pronounced. Using protocol to functionally isolate I<sub>Kur</sub><sup>41,46</sup>, it was found that outward K<sup>+</sup> currents generated were, like recombinant currents, inhibited by application of H<sub>2</sub>S generated via the NaHS donor. This inhibition occurred over a wide range of activating test potentials (Fig. 3a, b). The inhibitory effect






**Fig. 3 H<sub>2</sub>S inhibits native Kv1.5/I<sub>Kur</sub> currents in HL-1 and resulted in prolongation of AP.** **a** Current-density versus voltage relationships before (open circles) and during (solid circles) exposure to H<sub>2</sub>S-releasing donor NaHS (300 μM; n = 8, mean ± s.e.m.). **b** Families of outward K<sup>+</sup> currents recorded in an example HL-1 cell, before (right) and during exposure to H<sub>2</sub>S (left, 300 μM). **c** Bar graph showing percentage normalized mean (±s.e.m.) effect of NaHS (300 μM) and Kv1.5 inhibitor DPO-1 (1 μM) on outward K<sup>+</sup> currents peak amplitude measured at +50 mV. **d** Examples showing control recordings (black) and the effect of H<sub>2</sub>S (grey, left) or DPO-1 (grey, right). Scale bars apply to all families of currents 0.1 nA (vertical) and 50 ms (horizontal). **e** Cumulative APD<sub>90</sub> data (mean, ± s.e.m.) recorded from HL-1 cells or in adult rat atrial cells before (control, unfilled) and during application of 300 μM NaHS (filled). **f** Superimposed evoked APs (N = 20) before (black) and during 100 μM NaHS (grey) perfusion in HL-1 cells or **g** in rat atrial myocyte. For all panels paired *t* test; \**P* < 0.05, \*\**P* < 0.01.

of H<sub>2</sub>S on Kv1.5/I<sub>Kur</sub> at +50 mV test potential was similar to that observed for recombinant channels (38.3 ± 7.2 and 29.8 ± 3.1% respectively). These outward K<sup>+</sup> currents were also strongly inhibited when DPO-1 was used (Fig. 3c, d). Further evidence of the contribution of Kv1.5/I<sub>Kur</sub> to the K<sup>+</sup> outward currents obtained via applying H<sub>2</sub>S followed by DPO-1. Using this approach, H<sub>2</sub>S caused an inhibition of the K<sup>+</sup> current with cumulative mean inhibition of 31.8% ± 4.07% (n = 5), measured at +50 mV test potential, close to that seen above (29.8 ± 3.1%). Following the perfusion of DPO-1 and in the presence of H<sub>2</sub>S, there was a further small inhibition of 8.8% (n = 5), although this was not statistically significant (Supplementary Fig. 5d, e).

Moreover, under current clamp conditions, we assessed the effect of H<sub>2</sub>S on evoked APs in HL-1 atrial cells (Fig. 3f) and in adult rat (Fig. 3g) isolated atrial cardiomyocytes, where Kv1.5 expression has been established<sup>47</sup>. Measured APD<sub>90</sub> significantly increased in both cell types; from 86.9 ± 23.2 to 118.7 ± 30.7 ms

(n = 8, *p*-value = 0.006; two-tailed paired *t* test) in HL-1 cells with no significant change in membrane potential before (−61.6 ± 3.6 mV) or during (−63.1 ± 4.3 mV) exposure to H<sub>2</sub>S, and from 33.5 ± 6.09 to 69.7 ± 12.1 ms (n = 13, *p*-value = 0.007; two-tailed paired *t* test) in isolated rat atrial myocytes, with no significant change to membrane potential before (−78.9 ± 1.9 mV) or during (−75.4 ± 1.9 mV) exposure to H<sub>2</sub>S, (n = 13). Similar effects on APD in isolated rat atrial myocytes were seen when DPO-1 was used (Supplementary Fig. 5a). Taken together these data suggest that H<sub>2</sub>S can act as a regulator of this channel in these atrial tissues.

**Cellular remodeling stringency is reduced when H<sub>2</sub>S is present during pacing HL-1 cardiomyocytes.** Given the reported cardioprotective role of H<sub>2</sub>S<sup>48,49</sup>, we proceeded to examine its effect on paced HL-1 cells incubated with the H<sub>2</sub>S slow-release molecule,



**Fig. 4 H<sub>2</sub>S reduced electrical and cellular remodeling in paced HL-1 atrial cardiomyocytes.** **a** Representative AP recordings in spontaneously beating HL-1 cells from control cells that were not paced during the 8 h culture period (upper), cells that were paced at 5 Hz for 30 min regular intervals (middle) and paced cells that were incubated with slow-releasing H<sub>2</sub>S donor GYY4137 (lower). **b** Cumulative data showing mean (±s.e.m.) APD under control conditions ( $n = 11$ ), in paced cells ( $n = 10$ ), and in paced cells incubated with GYY4137 ( $n = 11$ ). \* $P < 0.05$ , \*\* $P < 0.01$ . **c** Representative western blots for native  $I_{Kur}$ /Kv1.5, and H<sub>2</sub>S producing enzymes CBS, CTH and MPST at different pacing time periods (2–8 hr) in the absence of GYY4137 or with incubation with GYY4137 (horizontal line), compared to control unstimulated conditions (0 h). β-actin was used as loading control in all western blots. **d** Mean (±s.e.m.) percentage change of band intensities following ( $n = 4$  experiments) at different pacing time periods (2–8 hr) in the absence of GYY4137 or with GYY4137 incubation, as indicated by the horizontal line.

GY4137. Samples were collected at various time intervals and compared to paced cells without the addition of H<sub>2</sub>S for a total of examined pacing period of 8 h. The electrophysiological remodeling observed in HL-1 cardiomyocytes, characterised by shortening of the spontaneous APs after high frequency pacing in culture, was reduced when H<sub>2</sub>S was present in the media during pacing. Figure 4a, shows spontaneous APs recorded from a control unstimulated cell (upper), paced cell (middle), and a cell where H<sub>2</sub>S was present throughout the pacing protocol (lower). Importantly, there was no significant difference in APD between control cells and paced cells that were supplemented with H<sub>2</sub>S

donor GYY4137 (Fig. 4b). The mean ± SEM of APD<sub>50</sub> and APD<sub>90</sub> values for control unstimulated cells were  $139.1 \pm 7.1$  ms and  $306.9 \pm 35.9$  ms ( $n = 11$ ) and for paced cells where H<sub>2</sub>S was present throughout the pacing protocol were  $153.6 \pm 8.6$  ms and  $244.3 \pm 13.76$  ms ( $n = 11$ ;  $p$ -value = 0.277 and 0.117 respectively; two-tailed unpaired  $t$  test).

We also investigated the effect of H<sub>2</sub>S on the pacing induced changes in the expression of Kv1.5/ $I_{Kur}$  and H<sub>2</sub>S-producing enzymes (Fig. 1e–h) as shown in the western blot examples, the upregulation of Kv1.5 and the H<sub>2</sub>S-producing enzymes, CBS, CTH, and 3MPST were reduced by the presence of the H<sub>2</sub>S donor



GGY4137 during high frequency pacing (Fig. 4c), full blots of these can be found as a Supplementary Fig 6. Figure 4d shows the quantified mean  $\pm$  SEM of the cumulative data for paced cells with and without H<sub>2</sub>S, the presence of H<sub>2</sub>S effectively prevented the pacing-induced increase in expression of Kv1.5/I<sub>Kur</sub> and H<sub>2</sub>S-producing enzymes (relative to unstimulated cells) and when compared to DPO-1 GGY4137 appear more effective in reducing/preventing CBS and CTH (Supplementary Figs. 3 and 6). The prevention of Kv1.5/I<sub>Kur</sub> upregulation by H<sub>2</sub>S during the pacing period may explain (i) AP durations in these cells remained closer to the unstimulated controls and (ii) the reduced upregulation of H<sub>2</sub>S-producing enzymes.

**Inhibition of Kv1.5 by H<sub>2</sub>S requires NO formation and arises through S-nitrosylation.** H<sub>2</sub>S modulates target proteins, including ion channels, via several distinct mechanisms<sup>37</sup>, and in the cardiovascular system the reduced bioavailability of NO is associated with cardiac dysfunction, in particular, AF<sup>25</sup> and heart failure<sup>50</sup>. To investigate the potential involvement of NO in the inhibition of Kv1.5 by H<sub>2</sub>S, we examined its effects in HEK 293 hKv1.5-expressing cells that had been pre-exposed to L-NAME (1 mM, 1 h at 37 °C), to inhibit NO formation via the inhibition of NO synthase, and tritiribine, to prevent NO formation via inhibition of Akt<sup>51</sup> (5  $\mu$ M, 30 min at 37 °C). As illustrated in Fig. 5a, the inhibition of NO formation prevented inhibition of hKv1.5 by H<sub>2</sub>S applied via NaHS (300  $\mu$ M). Time series examples shown in Fig. 5b and in Supplementary Fig. 7c, with cells pre-exposed to either L-NAME or tritiribine.

In control conditions and before the perfusion of H<sub>2</sub>S via NaHS, the measured currents amplitudes in both cells were stationary with coefficient of variation of 4% in Fig. 5b where the cell was pre-treated with L-NAME, and 4.3% in Fig. 5c where the cell was pre-treated with tritiribine, and 4.2% (Fig. 5b) or 0.8% (Fig. 5c) following the perfusion of NaHS and measured during the last 2.5 min of the recording. Furthermore, H<sub>2</sub>S treatment of HEK 293 hKv1.5-expressing cells resulted in a time dependent increase in phosphorylation of eNOS at position Ser1177 (Fig. 5d), the full blots can be found as a Supplementary Fig 7a, eNOS has been shown to regulate NO synthesis by activation of phosphorylation at this position<sup>52,53</sup>. These findings suggest NO is required for H<sub>2</sub>S to inhibit Kv1.5. In further support of this requirement, previous studies have demonstrated that recombinant Kv1.5 is inhibited by the NO-donor S-Nitroso-N-acetyl-DL-penicillamine<sup>40</sup> (SNAP; 100  $\mu$ M;  $n = 4$ ), we have confirmed this finding, in close agreement with the earlier study with inhibition of  $15.8 \pm 5.2\%$ .

Since S-nitrosylation is considered to play a role in cardioprotection<sup>54,55</sup> we examined this role further using the biotin switch assay<sup>56,57</sup>. H<sub>2</sub>S exposure via application of NaHS led to S-nitrosylation of the hKv1.5 channel, this modification was reduced in HEK 293 hKv1.5 expressing cells that were pre-treated with L-NAME for 1 h or tritiribine for 30 min before and during H<sub>2</sub>S exposure (Fig. 5e), the full blots can be found as a Supplementary Fig 7b.

## Discussion

Here we provide the modulation of Kv1.5/I<sub>Kur</sub> by H<sub>2</sub>S, and propose a role for this gasotransmitter in protecting against cellular and electrophysiological remodelling produced by high frequency pacing. Protection occurs via the inhibition of the atrial ultra-rapid outward rectifying current (I<sub>Kur</sub>) and its underlying Kv1.5 channel. HL-1 cardiomyocytes have previously been used successfully for the in vitro modelling of AF<sup>9,58,59</sup> with high frequency pacing reproducing many features of in vivo tissue

remodelling. Some of these features have been shown to be mediated by oxidative stress<sup>60</sup>.


In the present study, interval pacing has resulted in electrophysiological remodeling of HL-1 cells, including irregular activity and a significant APD shortening (Fig. 1). The APD shortening is a common characteristic of atrial remodelling in AF<sup>12</sup>, and here it was observed in all examined cells subjected to high frequency pacing. This would be expected to make cardiac tissue substrate more capable of sustaining a re-entrant arrhythmia<sup>61</sup>. Within cardiac tissue, cells with such high frequency irregular bursting could act as a trigger for arrhythmia initiation.

Another characteristic of AF remodeling is the altered tissue expression of ion channels<sup>3,13</sup>. We show an enhanced expression of Kv1.5/I<sub>Kur</sub> following the interval pacing conditions used in this study (Fig. 1e). This upregulation would contribute to the shortening of APD and creating a reduced effective refractory period, thus increasing the likelihood of re-entrant arrhythmias. Increased expression of Kv1.5 in rat cardiomyocytes has been implicated in development of arrhythmias and also caused APD shortening<sup>62</sup>.

In addition, we also observed the upregulation of protein expression of the H<sub>2</sub>S-producing enzymes; CTH, CBS and 3MPST (Fig. 1g). The increased production of such enzymes might act as a feedback mechanism, accelerating an increase in the cellular levels of H<sub>2</sub>S and consequently, offering a reduction in the remodeling effects. Such a protective role has been proposed by several studies in various diseases, including cardiovascular disease<sup>35</sup>. H<sub>2</sub>S is a modulator of diverse cardiovascular functions; it provides cardioprotection against ischemia/reperfusion (I/R) injury<sup>63,64</sup> and it causes vasodilation through K<sub>ATP</sub> activated channel sulphydration and activation<sup>43</sup>. However, its acute vascular effects also include an endothelium-dependent component<sup>65</sup>, which may involve NO production or activity<sup>66</sup>. Most strikingly, the deletion of H<sub>2</sub>S-producing enzyme CTH resulted in hypertensive mutant mice, implicating H<sub>2</sub>S as having a role as a physiological regulator of blood pressure<sup>42</sup>. Although H<sub>2</sub>S has been demonstrated to be effective in the regulation of coronary circulation, its importance is not fully established<sup>65</sup>, in particular its involvement in coupling flow to metabolism has yet to be explored.

Class I and III anti-arrhythmic agents, act on Nav1.5, to prolong the AP, but are only partially effective at restoring normal atrial rhythm, and can trigger life threatening ventricular arrhythmias<sup>30</sup>. Therefore, current attention in pharmacological management of AF is focused on identifying selective targeting of cardiac ion channels which are expressed mainly in the atria, including Kv1.5<sup>67,68</sup>. Results to date are promising, as Kv1.5 inhibition restores atrial contractility in animal models of AF<sup>29,69,70</sup>. This occurs even though its functional expression is reduced in chronic AF, and despite the complexity of remodelling in AF<sup>71–73</sup>. Targeting the oxidative regulation of Kv1.5 (either its acute oxidative augmentation of activity or controlling its oxidant-induced internalization/degradation) represents a novel and potentially important strategy for regulating its functional expression and activity as an approach to the management of AF.

Examination of the modulation of Kv1.5 by H<sub>2</sub>S, both in isolation and in established model of AF (Figs. 2 and 3) demonstrate that H<sub>2</sub>S inhibits stably expressed Kv1.5 in HEK293 cells. This direct inhibition was seen using whole cell patch clamp recordings as a slow progressive inhibition reaching a steady-state within 4–5 min and it was not reversed (Fig. 1). Combination of both perfused H<sub>2</sub>S and NO generated within the cell may contribute to the irreversible effect observed here. Interaction between H<sub>2</sub>S and NO modulation mechanism is essential in their regulatory action<sup>74–78</sup>. For example, sulfanyl (HS<sup>•</sup>) and nitrogen



**Fig. 5 Inhibition of Kv1.5 by H<sub>2</sub>S requires NO formation and nitrosylation of hKv1.5.** **a** Cumulative data showing the percentage inhibition (mean  $\pm$  s.e.m.) induced by the H<sub>2</sub>S donor NaHS on normalized hKv1.5 peak amplitude in HEK293, currents evoked by repeated step depolarizations from  $-70$  mV to  $+50$  mV (100 ms duration, 0.2 Hz) in untreated ( $n = 8$ ), L-NAME (1 mM; 1 h, 37 °C;  $n = 8$ ) or triciribine pre-treated cells (5  $\mu$ M; 1 h, 37 °C;  $n = 8$ ) \*\* $P < 0.01$ , \*\*\* $P < 0.001$ . **b, c** Example time-series plots showing the lack of effect of H<sub>2</sub>S donor NaHS during perfusion on normalized peak current amplitudes obtained from either L-NAME or Triciribine pre-treated HEK293 cell stably expressing human Kv1.5 (hKv1.5). Inset shows example currents before and during NaHS exposure (horizontal scale bar = 50 ms). **d** Representative western blots showing the time dependent effect of NaHS treatment on eNOS phosphorylation at Ser 1177 (upper), eNOS expression (middle).  $\beta$ -actin used as loading control (lower). Cell lysates obtained from H<sub>2</sub>S treated HEK293 cell stably expressing hKv1.5 at the time indicated, control represent cells not exposed to H<sub>2</sub>S. **e** Western blot showing detection of Kv1.5 nitrosylation via the biotin-switch assay.

monoxide (\*NO) chemical interaction generate thionitrous acid<sup>79</sup> (HSNO), in turn this would produce bisulfide (HS<sup>-</sup>) that could alter protein function when nitrosating biomolecules present.

H<sub>2</sub>S also inhibited K<sup>+</sup> currents in HL-1 cells, these K<sup>+</sup> currents were extremely sensitive to the selective Kv1.5 blocker DPO-1, consequently, the inhibitory effect of H<sub>2</sub>S on these outward K<sup>+</sup> currents is likely to be predominantly on the activity of Kv1.5 in these cells (Fig. 3a–d and Supplementary Fig. 5d, e). Additionally, APs in HL-1 cells were elongated when H<sub>2</sub>S was applied (Fig. 3e, f and Supplementary Fig. 5c). These cells exhibit some APs with spontaneous diastolic depolarization phase. Spontaneous depolarization is often due to hyperpolarization activated current

(HCN), shown to be expressed in these cells<sup>80</sup>. The HCN current appears to be enhanced by nitric oxide<sup>81,82</sup>, accordingly it is reasonable to assume some activation via NO occurring of HCN following H<sub>2</sub>S application (Fig. 3f). However, there are multiple ionic conductances contribute to the diastolic depolarization and dispute as to the relative roles of calcium clock and membrane (potassium delayed rectifier currents deactivation, HCN) mechanisms involved in this diastolic phase<sup>83,84</sup>. While these data do not eliminate the effect of H<sub>2</sub>S on other cardiac ion channels, and indeed several such ion channels are known to be H<sub>2</sub>S-sensitive<sup>43</sup>, the fact that the prolongation of APD by H<sub>2</sub>S in healthy rat atrial myocytes and healthy HL-1 cardiomyocytes

significantly mimics the effect of DPO-1 (Supplementary Fig. 5b) emphasizes the role of regulation of Kv1.5.

The proposed regulation of Kv1.5 by H<sub>2</sub>S could potentially be of physiological significance in regulating atrial excitability and supports a putative selective therapeutic role for Kv1.5 inhibition in AF. The supplementation of H<sub>2</sub>S donor GYY4137 into HL-1 cells remodeled by high frequency pacing eliminates or reduces the cellular remodelling changes detected previously (Fig. 4). This is consistent with the cardioprotection effect of H<sub>2</sub>S and adds to the data supporting the importance of H<sub>2</sub>S as a signalling molecule<sup>35,36</sup>. H<sub>2</sub>S donors resulted in oxidative stress reduction and also to the prevention of angiotensin II induced cardiac hypertrophy in rat myocytes<sup>68,85–87</sup>. The particular cellular cardioprotective mechanism of GYY4137 remains unknown. However, the release of low concentration of H<sub>2</sub>S by this donor over a long period of time<sup>88</sup> and thus it is present during the examined period of HL-1 pacing could provide continuous supply of H<sub>2</sub>S that act as a strong scavenger for peroxynitrites<sup>89</sup> thus eliminating their damaging effect<sup>90</sup>. Moreover, H<sub>2</sub>S allows reduction of disulfide bonds<sup>91</sup> and could act as a reducing agent when reactive intermediates present, generating products that offer an additional non-enzymatic pathway that results in increased NO bioactivity. These intermediates products include Nitroxyl<sup>92</sup>, nitrosopersulfide<sup>93</sup> and thionitrous acid<sup>79</sup>.

The inhibition of hKv1.5 channels expressed in HEK293 cells by bath application of two distinct H<sub>2</sub>S donors examined on single cell level (Fig. 2) and the significant reduction of this effect when NO formation was prevented by pre-treatment of cells with L-NAME and Triciribine (Fig. 5) suggesting that H<sub>2</sub>S acts, at least in part, via NO formation. In addition, biochemical measures revealed that H<sub>2</sub>S treatment of HEK293 cells expressing hKv1.5 resulted in a time dependent increased activation of eNOS, a prerequisite enzymatic mechanism for NO production, via phosphorylation of position Ser1177<sup>94</sup>. This phosphorylation was apparent (Fig. 5d) even from 5 min exposure to H<sub>2</sub>S, showing a faint band and reaching peak at time 30 min, demonstrating H<sub>2</sub>S dependent activation of NOS.

Interestingly, maintenance or augmentation of NO bioavailability is also considered a viable approach in the treatment of AF<sup>20,40</sup>. Furthermore, a post-translational modification of cysteine residues by S-nitrosylation, involved in forming –SNO groups by NO, has emerged as an important feature of NO signalling. Enhanced S-nitrosylation levels were detected when H<sub>2</sub>S and NO, applied via SNAP, were both used together during reperfusion of mouse hearts, suggesting that the protective effect of H<sub>2</sub>S was dependent on NO signalling<sup>95</sup>.

Other cardiac channel proteins were found to be regulated by S-nitrosylation as a mechanism to enable cardioprotection, for instance, enhancement of the Na<sup>+</sup> current<sup>96</sup> and the inhibition of the  $\alpha_1C$  subunit of the L-type Ca<sup>2+</sup> channel<sup>97</sup>. We have detected S-nitrosylation of hKv1.5 using the biotin switch assay following HEK293 cells expressing hKv1.5 treatment with the H<sub>2</sub>S donor, NaHS, once again, this S-nitrosylation was reduced when NO formation was prevented (Fig. 5d). Kv1.5 S-nitrosylation was suggested<sup>40</sup>, but not demonstrated, to occur in the voltage-sensor region of the channel, at either C331 and/or C346 and stabilized by I262 and R342, and thus may effect conformational change of Kv1.5 protein.

Our data indicate that exposure to H<sub>2</sub>S increases NO production through an increased phosphorylation of eNOS at Ser1177. An increase in H<sub>2</sub>S levels may promote a possible AF treatment through increased NO bioavailability and S-nitrosylation as a mechanism for H<sub>2</sub>S-mediated inhibition of hKv1.5.

We provide insight into the influence H<sub>2</sub>S on the modulation of Kv1.5, which is associated with adverse electrical remodelling

in AF, the reduced remodeling observed following H<sub>2</sub>S donor GYY4137 supplementation offer a potential therapeutic value for H<sub>2</sub>S being a regulator of the atrial excitability especially as the incidence of AF increases with age<sup>98</sup> and bioavailability of NO<sup>25</sup> and H<sub>2</sub>S<sup>99</sup> decreases.

## Methods

**Cell culture.** HL-1 atrial cardiomyocytes (Sigma, UK) were maintained in Claycomb media supplemented with batch specific FBS (10%), norepinephrine (0.1 mM), penicillin/streptomycin (1%), and l-glutamine (2 mM). Cells were cultured in flasks, or on coverslips that has been pre-treated with gelatin from bovine skin (0.02%) and fibronectin (5  $\mu$ g ml<sup>-1</sup>). HEK293 cells expressing Kv1.5<sup>41</sup> were maintained in minimum essential medium supplemented with fetal calf serum (10%), non-essential amino acids (1%), antibiotic antimycotic mix (1%) gentamicin (50  $\mu$ g ml<sup>-1</sup>), and blasticidin (5  $\mu$ g ml<sup>-1</sup>). All cells were cultured at 37 °C in a humidified atmosphere containing 95% air and 5% CO<sub>2</sub> and passaged when reached confluency.

**HL-1 pacing.** HL-1 cells were seeded onto a four well plates or coverslips and incubated at 37 °C in a humidified atmosphere (95% air and 5% CO<sub>2</sub>) with media being replaced every 24 h until visible beating was seen under microscopic examination. Cells were then subjected to electrical field stimulation using a C-Pace EM, a multi-channel culture pacer, (IonOptix, Milton, MA, USA), and incubated at 37 °C in a humidified atmosphere (95% air and 5% CO<sub>2</sub>) for 8 h. To induce tachycardia HL-1 cardiomyocytes were paced at 5 Hz with 5-ms duration square wave (40 V). The protocol lasted for a total of 8 h and pacing was applied for 50% of the time (30 min/hour). In some experiments, where H<sub>2</sub>S effect was examined, GYY4137 (50  $\mu$ M) was added to the media for the experiment duration. The cellular changes induced by pacing in HL-1 cells were assessed by collecting time course samples at 2, 4, 6 and 8 h and compared to the same cell population that was not subjected to pacing. Cell samples were lysed in M-perTM (Perbio Science, UK) with added tablet of complete mini protease inhibitors (Roche Diagnostics UK, UK). Cell lysate were cleared by centrifugation and stored at –20 °C until needed.

**Isolation of rat atrial myocytes.** Wistar rats (150–200 g) were humanely euthanized in accordance with UK Home Office Guidance on the Operation of Animals (Scientific Procedures) Act 1986 and with university of Leeds Ethical Review Committee approval (AWCNRWDS130706). Isolated hearts were perfused with Tyrode solution<sup>100,101</sup>, following the initial collagenase digestion, the atrial tissue was removed and cut into small pieces in a collagenase-BSA containing solution and gently agitated at 37 °C. Atrial cell suspension with rod-shaped cells were collected by filtration through nylon gauze and gentle centrifugation. Cells were washed in Tyrode solution containing 0.4 mM Ca<sup>2+</sup> and re-suspended in the same solution containing 0.7 mM Ca<sup>2+</sup>. All experiments were executed at room temperature (20–22 °C).

**Electrophysiology.** HL-1 cells attached to glass coverslip fragments were placed in a recording chamber (2–4 ml/min; 200  $\mu$ l volume) on the stage of an inverted microscope (Olympus CK40; Olympus, London, UK). Rat atrial myocytes were allowed to settle for 10 min before perfusion then perfused with extracellular solution (mM; 140 NaCl, 4 KCl, 1.8 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 5 glucose, 10 HEPES, pH 7.4). Electrodes were filled with internal solution (mM; 140 KCl, 10 NaCl, 4 MgCl<sub>2</sub>, 20 EGTA, 10 HEPES, pH 7.2), and the resistance was between 4–6 M $\Omega$  when filled. An agar bridge was made of 3 M KCl and used to stabilise the reference electrode when H<sub>2</sub>S was applied. Whole cell configuration for voltage or current clamp experiments were established, recorded, digitized and stored with an Axopatch 200B amplifier, Digidata 1322 A and pCLAMP 10 respectively (Molecular Devices, Union City, CA, USA).

Recordings from HEK293 cells expressing human Kv1.5 or native I<sub>Kur</sub> from HL-1 cardiomyocytes were obtained using established protocols<sup>41,46</sup>. Action potentials (APs) were recorded either in gap-free mode for the Spontaneous AP or through current injections to trigger them. Signals were low pass filtered at 2 kHz and sampled at 10 kHz. All recordings were done at room temperature. For H<sub>2</sub>S application Sodium hydrosulfide (NaHS; Sigma-Aldrich, Dorset, UK) was freshly made on the day of the experiment and dissolved in water to make 100 mM stock solutions, further dilutions were made in the perfusate solution to the desired test concentrations. GYY4137 Dichloromethane complex (Sigma-Aldrich, Dorset, UK), is a donor slowly releasing H<sub>2</sub>S over time, was prepared as instructed by the supplier and used for experiments that required a longer incubation time.

**Biotin-switch assay.** S-nitrosylation was detected using biotin-switch assay<sup>56,57</sup>. HEK293 cells expressing hKv1.5 were grown in T75 flasks until near confluency before being treated with freshly prepared NaHS (300  $\mu$ M) for 30 min at 37 °C. For experiments that involved L-NG-nitroarginine methyl ester (L-NAME; 1 mM) or Triciribine hydrate (5  $\mu$ M), cells were preincubated with either drug for 1 h at 37 °C before NaHS treatment. Control untreated cells were grown in separate incubator to that of NaHS experiments to avoid H<sub>2</sub>S gas contamination. Cells were lysed in a



non-denaturing lysis buffer (in mM: Tris-HCl 50, NaCl 300, EDTA 5, and Triton-X 1%), protease inhibitor cocktail tablets were added to all buffers used (Roche, Welwyn Garden City, UK). The following steps performed in the dark; to make free thiols unreactive, methyl methanethiosulfonate (MMTS) was used, then, nitrosothiols were selectively reduced with sodium ascorbate (1 mM) to reform thiol and labelled using biotin (biotin-HPDP, Pierce, Loughborough, UK). Biotinylated proteins were then purified using avidin-affinity chromatography, subjected to SDS-PAGE and detection via western blotting according to the manufacturer's instruction (Bio-Rad, UK).

**Immunoblotting.** Protein concentrations in cleared cell lysates were determined using a BCA assay (Pierce, USA). Samples (30 µg protein) were loaded on precast mini-protein gels 4–20% gradient and subjected to electrophoresis then transferred to PVDF membranes according to the manufacturer's protocols (Bio Rad, Hertfordshire, UK). Membranes were blocked with 5% non-fat milk protein in TBS-Tween (TBS, 0.05%) for 1 h at room temperature and immunostained with the appropriate antibodies (1:1000 dilution; anti-CBS, Santa Cruz Biotechnology, UK, anti-Kv1.5 antibody, Neuromab, Davis, CA, anti-CTH or anti-3MPST, Sigma-Aldrich, Dorset, UK) in 1% non-fat milk protein in TBST (1 h at room temperature). Membranes were then washed (3 × 5 min in TBST) and afterward incubated with secondary antibody conjugated to horseradish peroxidase (anti-rabbit Ig for 3MPST and CTH or anti-mouse Ig for anti-Kv1.5 or CBS, both 1:5000 dilution; LI-COR Biosciences, UK) for 1 h at room temperature. Finally, membranes were again washed in TBST (3 × 5 min) and immunoreactive bands visualized using the enhanced chemiluminescence (ECL) detection system (LI-COR Biosciences, UK). Band intensities were measured using ImageJ analysis software.

**Statistical information.** Data were analyzed using Excel (Microsoft, UK) and Origin (Northampton, MA) software. Data are presented as mean ± SEM. For statistical comparisons Student's *t* tests or one-way ANOVA with Bonferroni's multiple-comparison test was used, with *p* < 0.05 taken as statistically significant in each case. 'n' indicates the number of cells and 'N' the number of APs.

**Reporting summary.** Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

## Data availability

The original contributions presented in the article/Supplementary figures and Supplementary data are included in this study, any further inquiries can be directed to the corresponding author.

Received: 11 October 2022; Accepted: 5 June 2023;

Published online: 19 June 2023

## References

- Cherry, E. M. & Evans, S. J. Properties of two human atrial cell models in tissue: restitution, memory, propagation, and reentry. *J Theor Biol* **254**, 674–690 (2008).
- Ozgen, N. & Rosen, M. R. Cardiac memory: a work in progress. *Heart Rhythm* **6**, 564–570 (2009).
- Bosch, R. F. et al. Ionic mechanisms of electrical remodeling in human atrial fibrillation. *Cardiovasc Res* **44**, 121–131 (1999).
- Zhang, H. et al. Role of up-regulation of IK1 in action potential shortening associated with atrial fibrillation in humans. *Cardiovasc Res* **66**, 493–502 (2005).
- Darkow, E. et al. Small Conductance Ca<sup>2+</sup>-Activated K<sup>+</sup> (SK) Channel mRNA Expression in Human Atrial and Ventricular Tissue: Comparison Between Donor, Atrial Fibrillation and Heart Failure Tissue. *Front Physiol* **12**, 650964 (2021).
- Wijffels, M. C. et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. *Circulation* **92**, 1954–1968 (1995).
- Garan, H. et al. Sustained ventricular tachycardia in recent canine myocardial infarction. *Circulation* **62**, 980–987 (1980).
- Oh, S. et al. Remodeling of ion channel expression in patients with chronic atrial fibrillation and mitral valvular heart disease. *Korean J Intern Med* **25**, 377–385 (2010).
- Mace, L. C. et al. Transcriptional remodeling of rapidly stimulated HL-1 atrial myocytes exhibits concordance with human atrial fibrillation. *J Mol Cell Cardiol* **47**, 485–492 (2009).
- Wang, W. et al. Nkx2.5/CARP signaling pathway contributes to the regulation of ion channel remodeling induced by rapid pacing in rat atrial myocytes. *Mol Med Rep* **14**, 3848–3854 (2016).
- Qian, L. L. et al. Changes in ion channel expression and function associated with cardiac arrhythmogenic remodeling by Sorbs2. *Biochim Biophys Acta Mol Basis Dis* **166247**, 2021 (1867).
- Schmidt, C. et al. Upregulation of K(2P)3.1 K<sup>+</sup> Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation. *Circulation* **132**, 82–92 (2015).
- Workman, A. J. et al. The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation. *Cardiovasc Res* **52**, 226–235 (2001).
- Cha, T. J. et al. Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. *Circulation* **113**, 1730–1737 (2006).
- Ni, H. et al. Populations of in silico myocytes and tissues reveal synergy of multiatrial-predominant K<sup>+</sup>-current block in atrial fibrillation. *Br J Pharmacol* **177**, 4497–4515 (2020).
- Fabritz, L. et al. Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. *Nat Rev Cardiol* **13**, 230–237 (2016).
- Wakili, R. et al. Recent advances in the molecular pathophysiology of atrial fibrillation. *J Clin Invest* **121**, 2955–2968 (2011).
- Iwasaki, Y. K. et al. Atrial fibrillation pathophysiology: implications for management. *Circulation* **124**, 2264–2274 (2011).
- Nattel, S. et al. Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective. *Circ Res* **127**, 51–72 (2020).
- Simon, J. N. et al. Compromised redox homeostasis, altered nitroso-redox balance, and therapeutic possibilities in atrial fibrillation. *Cardiovasc Res* **109**, 510–518 (2016).
- Kim, Y. M. et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. *Circ Res* **97**, 629–636 (2005).
- Dudley, S. C. Jr. et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. *Circulation* **112**, 1266–1273 (2005).
- Reilly, S. N. et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. *Circulation* **124**, 1107–1117 (2011).
- Wolke, C. et al. Redox control of cardiac remodeling in atrial fibrillation. *Biochim Biophys Acta* **1850**, 1555–1565 (2015).
- Cai, H. et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. *Circulation* **106**, 2854–2858 (2002).
- Carnicer, R. et al. Nitric oxide synthases in heart failure. *Antioxid Redox Signal* **18**, 1078–1099 (2013).
- Yang, K. C. & Dudley, S. C. Jr. Oxidative stress and atrial fibrillation: finding a missing piece to the puzzle. *Circulation* **128**, 1724–1726 (2013).
- Wettwer, E. et al. Role of I<sub>Kur</sub> in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. *Circulation* **110**, 2299–2306 (2004).
- Schmitt, N. et al. Cardiac potassium channel subtypes: new roles in repolarization and arrhythmia. *Physiol Rev* **94**, 609–653 (2014).
- Tamargo, J. et al. I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation. *Expert Opin Investig Drugs* **18**, 399–416 (2009).
- Ou, X. H. et al. Remodeling of Kv1.5 channel in right atria from Han Chinese patients with atrial fibrillation. *Med Sci Monit* **21**, 1207–1213 (2015).
- Christophersen, I. E. et al. Genetic variation in KCNA5: impact on the atrial-specific potassium current I<sub>Kur</sub> in patients with lone atrial fibrillation. *Eur Heart J* **34**, 1517–1525 (2013).
- Hayashi, K. et al. Functional Characterization of Rare Variants Implicated in Susceptibility to Lone Atrial Fibrillation. *Circ Arrhythm Electrophysiol* **8**, 1095–1104 (2015).
- Yang, Y. et al. Novel KCNA5 loss-of-function mutations responsible for atrial fibrillation. *J Hum Genet* **54**, 277–283 (2009).
- Polhemus, D. J. & Lefer, D. J. Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease. *Circ Res* **114**, 730–737 (2014).
- Andreadou, I. et al. The role of gasotransmitters NO, H<sub>2</sub>S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. *Br J Pharmacol* **172**, 1587–1606 (2015).
- Peers, C. et al. Modulation of ion channels by hydrogen sulfide. *Antioxid Redox Signal* **17**, 95–105 (2012).
- Dayal, S. et al. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. *Circ Res* **88**, 1203–1209 (2001).
- Kimura, H. Hydrogen sulfide: from brain to gut. *Antioxid Redox Signal* **12**, 1111–1123 (2010).
- Núñez, L. et al. Nitric oxide blocks hKv1.5 channels by S-nitrosylation and by a cyclic GMP-dependent mechanism. *Cardiovasc Res* **72**, 80–89 (2006).

41. Al-Owais, M. M. et al. Multiple mechanisms mediating carbon monoxide inhibition of the voltage-gated K<sup>+</sup> channel Kv1.5. *Cell Death Dis.* **8**, e3163 (2017).
42. Yang, G. et al. H<sub>2</sub>S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. *Science*. **322**, 587–590 (2008).
43. Zhao, W. et al. The vasorelaxant effect of H<sub>2</sub>S as a novel endogenous gaseous K(ATP) channel opener. *EMBO J* **20**, 6008–6016 (2001).
44. Casanini, E. D. Contribution of hydrogen sulfide to the control of coronary blood flow. *Microcirculation*. **21**, 104–111 (2014).
45. Lagrutta, A. et al. potent inhibitors of human Kv1.5 K<sup>+</sup> channels and ultrarapidly activating delayed rectifier potassium current. *J Pharmacol Exp Ther.* **317**, 1054–1063 (2006).
46. Gao, Z. et al. Inhibition of ultra-rapid delayed rectifier K<sup>+</sup> current by verapamil in human atrial myocytes. *J Mol Cell Cardiol* **36**, 257–263 (2004).
47. Dixon, J. E. & McKinnon, D. Quantitative analysis of potassium channel mRNA expression in atrial and ventricular muscle of rats. *Circ Res* **75**(2), 252–260 (1994).
48. Shen, Y. et al. The Cardioprotective Effects of Hydrogen Sulfide in Heart Diseases: From Molecular Mechanisms to Therapeutic Potential. *Oxid Med Cell Longev* **2015**, 925167 (2015).
49. Citi, V. et al. The Role of Hydrogen Sulfide and H<sub>2</sub>S-donors in Myocardial Protection Against Ischemia/Reperfusion Injury. *Curr Med Chem* **25**, 4380–4401 (2018).
50. Wu, D. et al. Amelioration of mitochondrial dysfunction in heart failure through S-sulphydration of Ca(2+)/calmodulin-dependent protein kinase II. *Redox Biol* **19**, 250–262 (2018).
51. Predmore, B. L. et al. Hydrogen sulfide increases nitric oxide production from endothelial cells by an akt-dependent mechanism. *Front Physiol* **2**, 104 (2011).
52. Boo, Y. C. et al. Shear stress stimulates phosphorylation of eNOS at Ser(635) by a protein kinase A-dependent mechanism. *Am J Physiol Heart Circ Physiol* **283**, H1819–H1828 (2002).
53. Lin, M. I. et al. Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production. *J Biol Chem* **278**, 44719–44726 (2003).
54. Lima, B. et al. S-nitrosylation in cardiovascular signaling. *Circ Res* **106**, 633–646 (2010).
55. Murphy, E. et al. Signaling by S-nitrosylation in the heart. *J Mol Cell Cardiol* **73**, 18–25 (2014).
56. Jaffrey, S. R. & Snyder, S. H. The biotin switch method for the detection of S-nitrosylated proteins. *Sci STKE* **86**, pl1 (2001).
57. Forrester, M. T. et al. Detection of protein S-nitrosylation with the biotin-switch technique. *Free Radic Biol Med* **46**, 119–126 (2009).
58. Brundel, B. J. Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. *J Mol Cell Cardiol* **41**, 555–562 (2006).
59. Ke, L. et al. HSPB1, HSPB6, HSPB7 and HSPB8 protect against RhoA GTPase-induced remodeling in tachypaced atrial myocytes. *PLoS One* **6**, e20395 (2011).
60. Yang, S. et al. TPEN prevents rapid pacing-induced calcium overload and nitration stress in HL-1 myocytes. *Cardiovasc Ther* **33**, 200–208 (2015).
61. Al-Owais, M. M. et al. Deterministic and Stochastic Cellular Mechanisms Contributing to Carbon Monoxide Induced Ventricular Arrhythmias. *Front Pharmacol* **12**, 651050 (2021).
62. Tanabe, Y. et al. Over-expression of Kv1.5 in rat cardiomyocytes extremely shortens the duration of the action potential and causes rapid excitation. *Biochem Biophys Res Commun.* **345**, 1116–1121 (2006).
63. Calvert, J. W. et al. Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. *Circ Res* **105**, 365–374 (2009).
64. Predmore, B. L. & Lefer, D. J. Hydrogen sulfide-mediated myocardial pre- and post-conditioning. *Expert Rev Clin Pharmacol* **4**, 83–96 (2011).
65. Cheng, Y. et al. Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. *Am J Physiol Heart Circ Physiol* **287**, H2316–H2323 (2004).
66. Li, L. & Moore, P. K. Putative biological roles of hydrogen sulfide in health and disease: a breath of not so fresh air? *Trends Pharmacol Sci* **29**, 84–90 (2008).
67. Pavri, B. B. et al. MK-0448, a specific Kv1.5 inhibitor: safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans. *Circ Arrhythm Electrophysiol.* **5**, 1193–1201 (2012).
68. Woods, C. E. & Olgin, J. Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation. *Circ Res* **114**, 1532–1546 (2014).
69. de Haan, S. et al. AVE0118, blocker of the transient outward current I<sub>to</sub> and ultrarapid delayed rectifier current I<sub>Kur</sub>, fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. *Circulation.* **114**, 1234–1242 (2006).
70. Ravens, U. & Wettwer, E. Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications. *Cardiovasc Res* **89**, 776–785 (2011).
71. Olschewski, A. & Weir, E. K. Redox regulation of ion channels in the pulmonary circulation. *Antioxid Redox Signal* **22**, 465–485 (2015).
72. Saitoh, S. et al. Hydrogen peroxide: a feed-forward dilator that couples myocardial metabolism to coronary blood flow. *Arterioscler Thromb Vasc Biol* **26**, 2614–2621 (2006).
73. Saitoh, S. et al. Redox-dependent coronary metabolic dilation. *Am J Physiol Heart Circ Physiol* **293**, H3720–H3725 (2007).
74. Ali, M. Y. et al. Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide? *Br J Pharmacol* **149**, 625–634 (2006).
75. Wu, D. et al. An Update on Hydrogen Sulfide and Nitric Oxide Interactions in the Cardiovascular System. *Oxid Med Cell Longev* **2018**, 4579140 (2018).
76. Coletta, C. et al. Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. *Proc Natl Acad Sci USA* **109**, 9161–9166 (2012).
77. Nagpure, B. V. & Bian, J. S. Interaction of Hydrogen Sulfide with Nitric Oxide in the Cardiovascular System. *Oxid Med Cell Longev* **2016**, 6904327 (2016).
78. Giuffrè, A. & Vicente, J. B. Hydrogen Sulfide Biochemistry and Interplay with Other Gaseous Mediators in Mammalian Physiology. *Oxid Med Cell Longev* **2018**, 6290931 (2018).
79. Filipovic, M. R. et al. Chemical characterization of the smallest S-nitrosothiol, HSNO; cellular cross-talk of H<sub>2</sub>S and S-nitrosothiols. *J Am Chem Soc* **134**, 12016–12027 (2012).
80. Sartiani, L. et al. Functional expression of the hyperpolarization-activated, non-selective cation current I(f) in immortalized HL-1 cardiomyocytes. *J Physiol* **545**, 81–92 (2002).
81. Wenker, I. C. et al. Nitric oxide activates hypoglossal motoneurons by cGMP-dependent inhibition of TASK channels and cGMP-independent activation of HCN channels. *J Neurophysiol* **107**, 1489–1499 (2012).
82. Yang, Q. et al. Hyperpolarization-activated, cyclic nucleotide-gated cation channels in Aplysia: Contribution to classical conditioning. *Proc Natl Acad Sci USA* **112**, 16030–16035 (2015).
83. DiFrancesco, D. The pacemaker current (I(f)) plays an important role in regulating SA node pacemaker activity. *Cardiovasc Res* **30**, 307–308 (1995).
84. Vassalle, M. The pacemaker current (I(f)) does not play an important role in regulating SA node pacemaker activity. *Cardiovasc Res* **30**, 309–310 (1995).
85. Liang, W. et al. ATP-sensitive K<sup>+</sup> channels contribute to the protective effects of exogenous hydrogen sulfide against high glucose-induced injury in H9c2 cardiac cells. *Int J Mol Med* **37**, 763–772 (2016).
86. Shao, M. et al. Protective effect of hydrogen sulphide against myocardial hypertrophy in mice. *Oncotarget.* **8**, 22344–22352 (2017).
87. Snijder, P. M. et al. Exogenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates angiotensin II-induced hypertensive heart disease in rats. *Br J Pharmacol* **172**, 1494–1504 (2015).
88. Lee, Z. W. et al. The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. *PLoS One* **6**, e21077 (2011).
89. Whiteman, M. et al. The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite 'scavenger'? *J Neurochem* **90**, 765–768 (2004).
90. Ohsawa, I. et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. *Nat Med* **13**, 688–694 (2007).
91. Vasas, A. et al. Kinetic and thermodynamic studies on the disulfide-bond reducing potential of hydrogen sulfide. *Nitric Oxide* **4**, 93–101 (2015).
92. Eberhardt, M. et al. H<sub>2</sub>S and NO cooperatively regulate vascular tone by activating a neuroendocrine HNO-TRPA1-CGRP signalling pathway. *Nat Commun* **5**, 4381 (2014).
93. Cortese-Krott, M. M. et al. On the chemical biology of the nitrite/sulfide interaction. *Nitric oxide: Biology and chemistry* **46**, 14–24 (2015).
94. Dimmeler, S. et al. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. *FEBS Lett* **477**, 258–262 (2000).
95. Sun, J. et al. Additive cardioprotection by pharmacological postconditioning with hydrogen sulfide and nitric oxide donors in mouse heart: S-sulphydration vs. S-nitrosylation. *Cardiovasc Res* **110**, 96–106 (2016).
96. Ueda, K. et al. Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex. *Proc Natl Acad Sci USA* **105**, 9355–9360 (2008).
97. Sun, J. et al. Hypercontractile female hearts exhibit increased S-nitrosylation of the L-type Ca<sup>2+</sup> channel  $\alpha_1$  subunit and reduced ischemia/reperfusion injury. *Circ Res* **98**, 403–411 (2006).
98. Cha, Y. M. et al. Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. *Circulation.* **109**, 2839–2843 (2004).
99. Watts, M. et al. Decreased bioavailability of hydrogen sulfide links vascular endothelium and atrial remodeling in atrial fibrillation. *Redox Biol* **38**, 101817 (2021).
100. Dallas, M. L. et al. Carbon monoxide induces cardiac arrhythmia via induction of the late Na<sup>+</sup> current. *Am J Respir Crit Care Med* **186**, 648–656 (2012).
101. Yang, Z. et al. Epac2-Rap1 Signaling Regulates Reactive Oxygen Species Production and Susceptibility to Cardiac Arrhythmias. *Antioxid Redox Signal* **27**, 117–132 (2017).

## Acknowledgements

This work was supported by a grant from Heart Research UK (grant number RG2663).

## Author contributions

M.M.A., D.S., and C.P. conceived the theory. M.M.A. and N.T.H. planned and performed the research and analysed finding. M.M.A. wrote the initial manuscript, M.L.D., A.V.H. and D.S. revised and verified analytical methods and manuscript. J.L. cloned hKv1.5 and J.L.S. made the initial cell line expressing hKV1.5 clone.

## Competing interests

The authors declare no competing interests.

## Additional information

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s42003-023-05016-5>.

**Correspondence** and requests for materials should be addressed to Moza M. Al-Owais.

**Peer review information** *Communications Biology* thanks Alain Labro, Jiali Wang, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Gene Chong.

**Reprints and permission information** is available at <http://www.nature.com/reprints>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023